Compare DexCom, Inc. (DXCM) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Centrus Energy Corp — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Centrus Energy Corp trades at $142.97 (market cap $2.91B). The key difference: DexCom, Inc. is far larger — about 10.9× Centrus Energy Corp's market cap, and DexCom, Inc. is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Centrus Energy Corp for 29 Days on average.
| DXCM | LEU | |
|---|---|---|
Market Cap | $31.86B | $2.91B |
Volume | 3,607,070 | 903,777 |
Sector | Health | Energy |
52-Week High | $92.34 | $436.00 |
52-Week Low | $54.84 | $138.18 |
Typical Hold Time | 62 Days | 29 Days |
Enterprise Value | $31.32B | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Centrus Energy (LEU) trades at $143.88, down 2.22% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18) but maintains profitability with 10.23% net margins. Recent news highlights Centrus' strategic position as the only US-licensed HALEU producer, benefiting from nuclear energy growth and Russian uranium import bans.
The investment case balances high growth potential in nuclear fuel supply against execution risks and premium valuation. Analyst consensus at $218.10 suggests 52% upside, but technical indicators and recent equity dilution from a $500 million offering present near-term headwinds. Success depends on contract execution and nuclear industry adoption timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
